Prilenia and the center conducting a platform trial of potential amyotrophic lateral sclerosis (ALS) therapies revealed that the company’s drug candidate pridopidine failed to meet statistical significance for the primary and secondary endpoints of the study. However, Prilenia said it plans to continue developing the selective sigma 1 receptor (S1R) agonist in ALS, while the investigator-initiated study’s sponsor said the drug showed potential for benefit in speech and other aspects of the neurodegenerative disease.
The Healey and AMG Center for ALS at Massachusetts General Hospital is conducting the HEALEY-ALS Phase II/III platform study...
